HOST SPECIES: | Rabbit |
SPECIES REACTIVITY: | Human, Mouse |
HOMOLOGY: | Predicted species reactivity based on immunogen sequence: Guinea pig: (94%), Rat: (94%), Bovine: (94%) |
IMMUNOGEN: | Anti-BACE antibody (2253) was raised against a peptide corresponding to 17 amino acids near the carboxy terminus of human BACE. The immunogen is located within the last 50 amino acids of BACE. |
TESTED APPLICATIONS: | ELISA, ICC, IF, IHC-P, WB |
APPLICATIONS: | WB: 1 μg/mL; IHC-P: 2.5 μg/mL; ICC: 10 μg/mL; IF: 20 μg/mL. Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry, Immunocytochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested. |
POSITIVE CONTROL: | 1) Cat. No. 1303 - Human Brain Tissue Lysate |
2) Cat. No. 1282 - 3T3/NIH Cell Lysate | |
PREDICTED MOLECULAR WEIGHT: | Predicted: 55kD Observed: 65kD (Post-modification: 4 N-linked glycosylation) |
VALIDATION: | Independent Antibody Validation in Cell lines (Figure 2) shows similar BACE expression profile in human cell lines detected by two independent anti-BACE antibodies that recognize different epitopes, 2253 against C-terminus domain and 32-238 against recombinant fragment protein. BACE proteins are detected in all the tested cell lines except K562 at different expression levels by the two independent antibodies. KO validation (Figure 6,9): Anti-BACE antibody (2253) specificity was further verified by BACE KO mice (figure6) and KO cell line (figure9). BACE signal was not detected in BACE KO mice and KO cell line. KD validation (Figure 7,8,10): Anti-BACE antibody (2253) specificity was verified by BACE specific siRNA knockdown. BACE signal in mouse brain injected with BACE siRNAs and DRG transfected with BACE siRNAs was disrupted in comparison with control. Overexpression validation (Figure 6): Anti-BACE antibody (2253) detected high expression levels of BACE in 293 cells transfected with hBACE or mBACE (figure6) as compared to eGFP transfected cells. |
ISOFORMS: | Human BACE has 6 isoforms, including isoform A (501aa, 55.8kD), isoform B (476aa, 52.9kD), isoform C (457aa, 51.1kD), isoform D (432aa, 48.2kD), isoform 5 (401aa, 45kD) and isoform 6 (376aa, 42.2kD). This antibody detects all human isoforms. Mouse BACE has only 1 isoform (501aa, 55.7kD). Rat BACE has only one isoform identified so far (501aa, 55.8kD). |
PURIFICATION: | BACE Antibody is Ion exchange chromatography purified. |
CLONALITY: | Polyclonal |
ISOTYPE: | IgG |
CONJUGATE: | Unconjugated |
PHYSICAL STATE: | Liquid |
BUFFER: | BACE Antibody is supplied in PBS containing 0.02% sodium azide. |
CONCENTRATION: | 1 mg/mL |
STORAGE CONDITIONS: | BACE antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
OFFICIAL SYMBOL: | BACE1 |
ALTERNATE NAMES: | BACE Antibody: ASP2, BACE, HSPC104, KIAA1149, Beta-secretase 1, Aspartyl protease 2, ASP2 |
ACCESSION NO.: | AF190725 |
PROTEIN GI NO.: | 6118538 |
GENE ID: | 23621 |
USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
BACKGROUND: | BACE Antibody: Accumulation of the amyloid-beta (Abeta) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. Abeta peptide is generated by proteolytic cleavage of the beta-amyloid protein precursor (APP) at beta- and gamma-sites by two proteases. APP is first cleaved by beta-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for gamma-secretase to generate the 4 kDa amyloid-beta peptide, which is deposited in the brains of all suffers of Alzheimer's disease. The long-sought beta-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2). BACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP. |
REFERENCES: | 1) Vassar et al. Science 1999;286:735-41 | 2) Hussain et al. Mol Cell Neurosci 1999;14:419-27 | 3) Yan et al. Nature 1999;402:533-7 | 4) Sinha et al. Nature 1999;402:537-40 |
CITATIONS: | 1)Singer et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005;8(10):1343-9. PMID: 16136043 |
2)Jo et al.Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging. 2010;31(6):917-25. PMID: 18687504 | |
3)Hyun. RNA Interference Against BACE1 Suppresses BACE1 and Aβ Expression in PC12 Cells and DRG Neurons. Stanford Journal of Neuroscience. 2007; 1(1):2-8.PMID: | |
4)Okada et al. Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 2010;24(8):2783-94PMID: 20354142 | |
5)Liu et al. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. Biochemistry. 2002;41(9):3128-36PMID: 11863452 | |
6)Colombo et al. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis. 2009;33(3):518-25PMID: 19166938 | |
7)Bettegazzi et al. β-Secretase activity in rat astrocytes:translational block of BACE1 and modulation of BACE2 expression. Eur J Neurosci. 2011;33(2):236-43.PMID: 21073551 | |
8)Lichtenthaler et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem. 2003;278(49):48713-9PMID: 14507929 | |
9)Lee et al. Secretion and intracellular generation of truncated Abeta in beta site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem. 2003;278(7):4458-66PMID: 12480937 | |
10)Rockenstein et al. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem. 2005;280(38):32957-67. PMID: 16027115 | |
11)Catania et al. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009;14(1):95-105PMID: 17912249 | |
12)Parisiadou et al.Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. Neurobiol Dis. 2008;30(3):353-64PMID: 18387811 | |
13)Knock et al. SUMO1 impact on Alzheimer disease pathology in an amyloid depositing mouse model. Neurobiol Dis. 2018;110:154-165PMID: 29217476 | |
14)Debatin et al. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis. 2008;5(6):347-54.PMID: 18349519 | |
15)Gwon etal. Selenium attenuates A beta production and A beta-induced neuronal death. Neurosci Lett. 2010;469(3):391-5. PMID: 20026385 | |
16)Kuhn et al. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta, and gamma-secretase. J Biol Chem. 2007;282(16):11982-95. PMID: 17307738 | |
17)Succol et al. A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. J Neurochem. 2007;103(1):380-7.PMID: 17877641 | |
18)Zhuo et al. Severe In vivo hyper-homocysteinemia is not associatedwith elevation of amyloid-beta peptides in the Tg2576 mice. J Alzheimers Dis. 2010;21(1):133-40. PMID: 20555139 | |
19)Zhuo et al. Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol.2010;45(3):195-201. PMID: 20005283 | |
20)Malnar et al. Cholesterol-depletion corrects APP and BACE1 misstrafficking in NPC1-deficient cells. Biochim Biophys Acta. 2012;1822(8):1270-83. PMID: 22551668 |
ANTIBODIES FOR RESEARCH USE ONLY.
For additional information, visit ProSci's Terms & Conditions Page.